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Background: Recognized public health relevant risk factors such as obesity, physical inactivity, smoking or air
pollution are common to many non-communicable diseases (NCDs). NCDs cluster and co-morbidities increase in
parallel to age. Pleiotropic genes and genetic variants have been identified by genome-wide association studies
(GWAS) linking NCD entities hitherto thought to be distant in etiology. These different lines of evidence suggest
that NCD disease mechanisms are in part shared.
Discussion: Identification of common exogenous and endogenous risk patterns may promote efficient prevention,
an urgent need in the light of the global NCD epidemic. The prerequisite to investigate causal risk patterns
including biologic, genetic and environmental factors across different NCDs are well characterized cohorts with
associated biobanks. Prospectively collected data and biospecimen from subjects of various age, sociodemographic,
and cultural groups, both healthy and affected by one or more NCD, are essential for exploring biologic
mechanisms and susceptibilities interlinking different environmental and lifestyle exposures, co-morbidities, as well
as cellular senescence and aging. A paradigm shift in the research activities can currently be observed, moving from
focused investigations on the effect of a single risk factor on an isolated health outcome to a more comprehensive
assessment of risk patterns and a broader phenome approach. Though important methodological and analytical
challenges need to be resolved, the ongoing international efforts to establish large-scale population-based biobank
cohorts are a critical basis for moving NCD disease etiology forward.
Summary: Future epidemiologic and public health research should aim at sustaining a comprehensive systems
view on health and disease. The political and public discussions about the utilitarian aspect of investing in and
contributing to cohort and biobank research are essential and are indirectly linked to the achievement of public
health programs effectively addressing the global NCD epidemic.
Keywords: Comorbidities, Cohort, Genome wide association study, Non-communicable disease, Phenome,
Public health, Risk factorsBackground
The aim of the present report is to address the importance
of studying non-communicable diseases (NCDs) and their
relationship to aging in a systems approach. Understanding
the complexity and interrelation of risk factors and disease
networks requires the biologic sample collection, detailed
and comprehensive phenotyping, and broad risk factor
data. We present the international progress made in estab-
lishing large population-based biobank cohorts with the
explicit aim to investigate non-communicable disease
(NCD) etiology longitudinally. We point to the current* Correspondence: medea.imboden@unibas.ch
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restricted use, distribution, and reproduction iinadequacy and the critical need to invest substantial
research funding into NCD research in low and middle
income countries in which the rise of NCDs converges
with the high prevalence of infectious diseases. We discuss
the relevance of studying pathophysiologic mechanisms
linking different age-related NCDs and the aging process.
We also highlight recent examples of phenome approaches.
Finally, we point out striking pleiotropic findings of NCD
phenotypic traits and genome-wide associations (GWAS)
which clearly signpost an on-going paradigm shift in NCD
research and underscore the potential of agnostic, complex
data, systemic and multi-levelled methodologies leading to
new understanding of chronic disease etiology.BioMed Central Ltd.Probst-Hensch This is an open access article distributed
tribution License (http://creativecommons.org/licenses/by/2.0), which permits un-
n any medium, provided the original work is properly cited.
Imboden and Probst-Hensch BMC Public Health 2013, 13:1094 Page 2 of 13
http://www.biomedcentral.com/1471-2458/13/1094International trend for prospective large-sized
biobank cohorts
NCDs convey more than 50% of the global burden of
disease and are challenging the health of populations
worldwide. In high income countries (HICs), the epidemic
of NCDs has been recognizably the major public health
challenge over the last decades [1]. For this reason several
HICs have increased their research efforts and invested
substantial funding in extremely large population-based
prospective cohort studies (with samples sizes over 200′
000). These mega-cohorts (Table 1; see also www.p3g.org)
apply detailed phenotype descriptions over time, exhaustive
temporal assessment of personal and environmental infor-
mation and include high quality biologic sample collections
for future genetic and functional analyses [2]. Prospective
biobanking represents a powerful tool for establishing
causal relationships as the time-order of sampling and
of phenotyping is generally clear. Both hypothesis-driven
as well as agnostic research can be conducted. Biologic
samples in research can be used to test genetic deter-
minants (e.g. genetic variants of N-Acetyltransferases,
NAT1 and NAT2) potentially mediating susceptibility
(e.g. increased cancer risk), to discover or validate bio-
markers as land marks of mechanisms (e.g. acetylation
of aromatic and heterocyclic amines), or to sense and
estimate individual environmental exposures (e.g. vari-
able toxicity of carcinogens). Additional applications are
expected to increase in the future. General good practices
for biobanking in research have been defined (e.g. www.
ieaweb.org for epidemiologic settings). An increasing need
for biologic samples has therefore been the driving force
to establish biobank collections in various clinical and
observational settings [3]. A well-known example is the
UK biobank, collecting blood, saliva and urine of more than
500′000 participants. Questionnaire and measurement data
were collected at baseline and follow-up examinations are
performed in subsets of the cohort [4]. There are also
efforts of similar dimension in low and middle income
countries (LMIC) such as the Chinese Biobank Study
[Kadoorie Study of Chronic Disease in China (KSCDC)].
This project is a blood-based health database aiming at
collecting genetic, environmental and lifestyle data on
510′000 adults aged 30–79 years to understand the causes,
risk factors, pathogenesis, prevalence patterns and trends
of major infectious and NCDs [5]. The establishment,
maintenance and repeated collection of participant data
require a substantial long-term investment of research
funds. Critical voices point to the tremendous costs and to
the methodological challenges to keep bias low over a long
follow-up time in a multi-centric study design. But the
scientific utility of such large longitudinal datasets is
undisputed [6,7]. Understanding the genetic, molecular
and mechanistic background of interdependence between
NCDs, comorbidities and risk factors during the agingprocess is a research priority for public health. Sufficiently
powered cohorts and biobanks with broad, yet refined
characterization of participants for risk factors and health
phenotypes are a conditio sine qua non to achieve this
goal.
Discussion
Biobank cohorts and chronic disease research in low
and middle income countries (LMIC)
Research on NCDs almost exclusively relies on cohort
data and associated biological samples collected in HICs.
The recent update of global burden of disease estimates
marks a shift from communicable towards non-commu-
nicable diseases and from life years lost due to premature
death to increased number of years lived with chronic
diseases and disabilities in LMICs [1,8]. Though regionally
heterogeneous, the LMICs show a persistently high
proportion of infectious diseases in addition to a recent
increase in prevalence of NCDs such as ischemic heart
disease, stroke and diabetes. This observed convergence of
NCDs and communicable diseases causes a dual burden
of disease [9] for which most LMICs not only lack
adequate health system resources, but also research funds
to address the regional and local public health challenges
[10]. Though causal relationships of NCD etiology and
preventive measures identified in population-based biobank
cohort studies in HICs will most likely inform public health
decisions in LMICs, it is obvious that repeating studies of
established NCD risk factors in LMICs will be necessary
for proper estimation of their contribution to the disease
burden [11]. Much can be learned about effect modifiers
and risk factors by paralleled establishment of biobank co-
horts in different settings. From human genome variation
studies we already know that many African populations
harbour a larger degree of genetic variation [12]. Several
examples of high quality cohort study efforts in LMIC
have been undertaken [7] (Table 1). For example, the
prevalence of healthy lifestyle in patients with cardiovascu-
lar disease (n = 7519) was investigated in the PURE study,
a large-scale epidemiological study that recruited >140,000
individuals residing in in 17 low-, middle-, and high-
income countries around the world, and revealed strong
correlation of decreasing levels of healthy lifestyle with
decreasing country income level [13]. The Guangzhou
Biobank Cohort Study [14], combining the use of bio-
markers and questionnaire data for investigation of NCDs
health system use as well as NCDs etiology, is another
excellent example of a regional population-based cohort
study in a country transiting fast from low to high income
settings, albeit with large social discrepancies. Such large
scale biobank cohort studies in LMICs face numerous
challenges including funding, political, cultural and re-
ligious issues, but they are imminently important to
collect data and monitor the dynamics of changes in
Table 1 Selection of ongoing mega-cohort studies in adults
Web site Cohort study Country Country size Focus Sample size Baseline Biologic samples
– CONOR/HUNT Norway 4,9 Mio Common disease etiology 185′000 1994-1995 Blood
http://www.millionwomenstudy.org/ Million women study United Kingdom 62,3 Mio Women’s health 1′300′000 1996 - 2001 Blood, saliva,
in a sub-sample
http://epic.iarc.fr/ EPIC Europe 738,2 Mio Nutrition, life style and cancer other
diseases
520′000 1997 Blood
– Mexico city prospective
study
Mexico 117,4 Mio Major determinants of morbidity
and premature mortality
150′000 1998-2004 Blood
http://www.decode.com/research/ deCODE Iceland 0.4 Mio Research company 200′000 2000 Various
http://www.milleniumcohort.org/ Millennium USA 313,3 Mio US military family cohort 150′000 2001 Not specified
http://www.geenivaramu.ee/en/ Estonian biobank Estonia 1.3 Mio Biologic resource 50′000 2002 Blood
http://www.birmingham.ac.uk/research/activity/
mds/projects/HaPS/PHEB/Guangzhou/index.aspx
Guanghzou Biobank
Cohort study
China 1339,7 Mio Genetic, lifestyle, occupational and
environmental factors, and life course
Causes of the common chronic
diseases
40′000 2003 Blood, urine
http://www.ckbiobank.org/ China Kandoorie Biobank China 1339,7 Mio Chronic disease etiology, complex
interplay of lifestyle, environmental,
and genetic susceptibility
500′000 2004-2008 Blood
http://www.phri.ca/pure/index.html PURE Several countries 3223,7 Mio Maladaptation to urbanization and
cardiovascular health
120′000 2006 Blood
http://www.ukbiobank.ac.uk/ UK biobank United Kingdom 62,3 Mio Common disease etiology 500′000 2007 - 2010 Blood, saliva, urine
http://www.lifelines.net/ LifeLines The Netherlands 16,8 Mio causes and prognosis of burden of
disease, co-determinants, rather
than comorbidity, family study
165′000 2007 Blood, urine
https://www.etude-nutrinet-sante.fr/fr/
common/login.aspx
Nutrinet Santé France 65,4 Mio Nutrition and health 500′000 2009 Blood, urine
http://www.partnershipfortomorrow.ca/ The Canadian Partnership
for Tomorrow Project
(CPTP)
Canada 34,4 Mio Cancer and chronic disease etiology 300′000 2009 Blood
http://lifegene.ki.se/ Life gene Sweden 9,4 Mio Nealth and lifestyle 500′000 2011 Blood, urine
http://www.constances.fr CONSTANCES France 65,4 Mio Biologic and research resource 500′000 2011 Blood
http://www.nationale-kohorte.de/index_en.html German national cohort Germany 81,8 Mio Common disease etiology 200′000 2012 Blood
Listed by date of baseline examination start.
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with the increasing trend of urbanization in these countries
[7]. They also contribute importantly to increasing the
global competitiveness of research in LMICs [15].
Phenome approach towards disease networks
In aiming to improve understanding of NCD etiology
refined phenotyping of specific health outcomes is a
necessity. Clinical disease diagnosis based research is
known to be challenged by phenotypic heterogeneity. As
an example, asthma, an intermittent chronic respiratory
disease can be defined as a clinical diagnosis of asthma,
but it is known that there are important differences in
etiology and mechanisms depending on age of asthma
onset or the presence of atopy and allergies. GWAS find-
ings clearly revealed that the locus 17q21 determined
childhood and not adult onset asthma [16,17]. Statistical
clustering approaches applied to the multilayer disease
characteristics of a large group of asthmatic patients
identified four distinct asthma phenotype groups: active
treated allergic childhood-onset asthma; active treated
adult-onset asthma; inactive or mild untreated asthma
differing by atopy status and age of asthma onset [18].
In general up to recently, genetic investigations of NCD
determinants, especially in large-scale GWAS meta-
analyses, reduced the phenotype studied to a clinical
diagnostic entity, a fact that may contribute to the dis-
appointingly low predictive power of common genetic
disease variants identified to date [19-21]. The importance
of precise phenotyping for identifying the genetic contribu-
tion to common disease has been stressed since the time
point of completion of the human genome project [22].
Clearly this challenges meta-analyses of data from different
medium-sized cohorts collected in non-harmonized ways.
International efforts to develop harmonized phenotype
definitions lead early on to the Human Phenome Project
[22,23]. Since the initiative call phenome based databases
were established (e.g. bipolar disorder phenome [24]; epi-
lepsy phenome/genome project [25]; mouse phenome [26];
human pathology centered phenomes on cardiomyopathy
[27], deafness [28], cardiac conduction characteristics [29],
human skeletal phenome [30]). Phenotypes forming the
basis of the phenome approaches can refer to any char-
acteristic or trait measureable in an organism. It can be
as diverse as a morphologic, biochemical, physiological,
electrical, behavioral, epigenetic trait and these measures
show a large inter-individual variability. Recently phenome-
based approaches proofed their usefulness in identifying
context-dependent clinical reference values for white blood
cell counts [31]. Other recent phenome approaches applied
semantic web technologies to scan electronic health records
comprising clinical and biologic medical data for identifying
genotype-phenotype associations [32,33]. The current ap-
plications of the phenome approaches illustrate well thebroad definition of the “phenome” summarizing often
a large collection of phenotypes. Refined phenome ap-
proaches must be expanded to the concept of disease
networks [34,35], the Diseasome. According to a European
population-based survey 25% of the respondents of age
older than 14 years reported the presence of more than
one chronic condition [36]. A systematic evidence review
reported prevalence ranges of multi-morbidity in elderly
of 55% to 98% [37]. The identification and clustering of
human disease etiologic factors was undertaken in a
bioinformatic driven data-mining approach using MeSH
annotation of MEDLINE-referenced articles and the au-
thors produced the etiome profile for 863 diseases (avail-
able at http://etiome.stanford.edu) [38]. New analytical
approaches open novel exploratory avenues of investigation
supporting the paradigm shift towards systematic, multi-
layered and more exhaustive phenotypic catalogs. Patient
records from a 1.5 million large patient population were
used to establish correlation links of 161 disorders with
disease phenotypes allowing to estimate the genetic overlap
within the disease network [39]. A comorbidity database,
the human disease network, was established from the
analysis of 30 Mio Medicare patient data linking diseases
and comorbidities (available at http://hudine.neu.edu/)
[40]. More recently, to better understand disease simi-
larities independent research groups have explored the
clustering of genome-phenome correlations on a large
number of published phenotype – gene associations [41],
or the type 2 diabetes genetic loci [42] or the major histo-
compatibility complex class II surface receptor, HLA-
DRB1 [43]. These reports clearly proof the huge potential
of bioinformatics-driven data-mining methodologies to
shape the diseasome by classification of disease pheno-
types and molecular diseases pathways. Thus such public
health relevant research will continue to steadily improve
our understanding of the phenotypic overlap of different
NCDs and their link to aging processes. These system ap-
proaches to disease must furthermore be paralleled by sys-
tems approaches to understand risk factors. The concept
of the phenome has thus been supplemented by the con-
cept of the Exposome which measures environmental ex-
posure as internal intermediate phenotypes of exposed
organisms [44-46] using metabolomic and proteomic
methods for quantification of molecular traits.
Accelerated aging processes as a link to NCD comorbidity
Given that NCDs are chronic the proportion of comor-
bidities or secondary NCDs increase with age. Beyond this
play of chance, NCD risk factors are known to accelerate
the aging process of various organs. Smoking and obesity
are among the most consistent factors showing adverse
effects on all features of aging. For example, smoking, a
potent risk factor for cardiovascular and respiratory NCDs
has been suggested to promote cellular senescence of the
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increase skin aging [49]. Likewise obesity, a major risk
factor for cardiovascular NCDs has been associated with
age-related disease of the CNS [50]. Telomere shortening,
a marker of the aging process, is inversely associated with
several risk factors of diabetes and mitochondrial function
in diabetic patients compared to healthy controls [51].
Telomere length was positively correlated with good
glycemic/lipid control and negatively correlated with adi-
posity and insulin resistance [51,52]. Other NCD risk
factors such as sun light or weight loss exhibit adverse
effects on more restricted features of aging such as skin
aging or osteoporosis (see Table 2 as illustrative example).
The natural history of aging is characterized by a
diminished self-renewal capacity of the organism resulting
in sclerodermatous changes of the skin, alopecia, osteopor-
osis, sarcopenia, muscle atrophy, generalized lipodystrophy,
atherosclerosis, decreased elasticity of the vascular system,
immunologic senescent changes such as decline in humoral
immunity, T-cell functional dysregulation, innate and adap-
tive immune functions [48,59,64,67]. Characteristic land
marks of aging are also neurologic senescent changes of
the central, peripheral and autonomic nervous system
including limited neuronal loss, glial proliferation in the
cortex and an overall brain weight decrease, degradation
of sensory performance, decline in proprioception and
somatosensory information processing and also reduced
reactivity of the sympathetic and the parasympathetic
nervous activity [68,69]. It is likely that systemic approaches
combining the focus on accelerated aging, NCDs, environ-
mental and genetic risk factors will point to the underlying
disease biology. Understanding how shared risk factors
affect mechanisms common to NCDs and aging processes
is important from a public health perspective to meet
effective prevention programs.
Lessons learned from genetics on NCD clustering:
pleiotropic gene variants
Despite ongoing debates about the limitation of GWAS
findings from the predictive personalized medicine perspec-
tive, GWAS studies do not announce the end of complex
disease genetics, but rather a promising first step. Com-
pletely novel genes expand our understanding of NCD
pathology. A large number of GWAS loci have been
consistently associated with one or multiple NCDs in
independent populations (see Additional file 1; www.
genome.gov/gwastudies). Evidence for pleiotropy of loci,
genes and even specific SNPs suggests important mechan-
istic links between diseases and is of potential relevance
to advance understanding the biology of NCD clusters,
co-morbidities and aging processes. A recent meta-analysis
of 372 GWAS on 105 unique age-related diseases revealed
the clustering of genetic variants in ten significantly
enriched chromosomal locations which contain genesinvolved in inflammation and cellular senescence [70].
Pleiotropy is defined as a genetic variant or a gene having
an effect on multiple phenotypes. In Table 3, we present
an overview of specific SNPs likely to be pleiotropic. They
were consistently associated with different forms of cancer
(i.e. rs401681,TERT, CLPTM1L, 5p15.33 – associated with
lung, bladder, pancreatic cancer, melanoma and prostate-
specific antigen levels) and of chronic inflammatory diseases
(i.e. rs11209026, IL23R, 1p31.3 – associated with Crohn’s
disease, ulcerative colitis, ankylosing spondylitis and
psoriasis; rs10488631, IRF5,TNPO3, 7q32.1 – associated
with systemic lupus erythematosus, systemic sclerosis,
rheumatoid arthritis and primary biliary cirrhosis; see
Additional file 2 for detailed summary of pleiotropic SNPs).
This observed non-random clustering of NCD-linked traits
and specific pleiotropic SNPs can be used to identify bio-
logic mechanisms shared by different NCDs. In a recent
study a method was presented to evaluate the pleiotropy
among GWAS-identified SNPs and genes for common
complex disease and traits; it reported that 17% of the
GWAS genes and 4% of the GWAS SNPs showed evidence
of pleiotropy [71]. Although pleiotropy had been suggested
to be common to the genetic architecture of complex
disease [72], only isolated cases of pleiotropy had been
reported previously such as the links between APOE
genotypes and dyslipidemia, coronary heart disease and
Alzheimer's disease [73], and type 2 diabetes and prostate
cancer (TCF2 genotypes) [74]. The genetic overlap between
psoriasis, diabetes type 2 and Crohn’s disease, three inflam-
matory diseases affecting distinct organs, was identified
by combining evidence from linkage and GWAS data
[75]. Recently antagonistic pleiotropic effects of genetic
variants were evidenced conferring risk for one disease,
diabetes type 1, and protection for another disease, inflam-
matory bowel disease [76].
Methodological challenge of data mining and
of complex systems analysis
The research community is facing unprecedented statistical,
data mining and analytical challenges as the next steps
ahead are complex interaction studies of genes, other –
omics markers, lifestyle, and environment on the phenome.
Standard statistical approaches using linear causal relation-
ships have shown to be limited for reproducible association
studies on complex phenotypes as well as for two-way
interaction analyses. Researchers will need to adapt their
current methods by implementing approaches that reflect
more closely the dynamics of adaptive biologic systems by
taking non-linear and non-proportional relationships into
account. Methods of complex system science and chaos
theory have been applied to various biologic systems [77]
and have been proposed to be applied to human health
behavioral changes for public health prevention aims [78].
Fractal dynamics in physiology have shown to be relevant
Table 2 Risk factors of NCDs and aging
Risk factor studied Disease or trait Acclerated aging and impaired function Reference
Smoking Humoral immunity Immune system aging [48]
Inflammatory response Immune system aging [53]
Heart rate variabiltiy Autnomous nervous system aging [54]
Alzheimer Premature cognitive impairment, CNS aging [55]
Atherosclerosis Cardiovascular aging [56]
Elastosis of the neck Skin aging [57]
Bone mineral density Bone aging [58]
Obesity, BMI, high calorie intake, Impaired immune response Immune system aging [59]
Waist-hip ratio, skin-folds, CD8 Tcell activation Immune system aging [59]
Body weight Lipodystrophy Adipocyte aging [60]
Heart rate variabiltiy Autnomous nervous system aging [61]
Alzheimer Premature cognitive impairment, CNS aging [55]
Atherosclerosis Cardiovascular aging [56]
Alopecia Hair aging [62]
Bone mineral density Bone aging [58]
Dyslipidemia Atherosclerosis Cardiovascular aging [56]
Alopecia Hair aging [62]
History of diabetes Alzheimer Premature cognitive impairment, CNS aging [55]
Bone mineral density Bone aging [58]
Hypertension, Alzheimer Premature cognitive impairment, CNS aging [55]
High resting pulse Atherosclerosis Cardiovascular aging [56]
Osteoporosis Bone aging [63]
Bone mineral density Bone aging [58]
Other chronic diseases, Immunosenescence Immune system aging [64]
Comorbidity Lipodystrophy Adipocyte aging [65]
Atherosclerosis Cardiovascular aging [56]
Sacropenia Muscle aging [66]
Osteoporosis Bone aging [63]
Medication intake Sacropenia Muscle aging [66]
Osteoporosis Bone aging [63]
UV light/sun exposure Alopecia Hair aging [62]
Low sun exposure Elastosis of the neck Skin aging [57]
Sacropenia Muscle aging [66]
Health behaviours Alzheimer Premature cognitive impairment, CNS aging [55]
Low level of mental activity Atherosclerosis Cardiovascular aging [56]
Physical inactivity Sacropenia Muscle aging [66]
Osteoporosis Bone aging [63]
Depression Atherosclerosis Cardiovascular aging [56]
Poor diet Sacropenia Muscle aging [66]
Weight loss/no weight gain Osteoporosis Bone aging [63]
Low education Alzheimer Premature cognitive impairment, CNS aging [55]
Atherosclerosis Cardiovascular aging [56]
Psychosocial factors Alzheimer Premature cognitive impairment, CNS aging [55]
Content of table is illustrative, not exhaustive.
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Table 3 Pleiotropic GWAS loci of NCDs
Locus, gene dbSNP ID NCD entity associated with SNP P-value Risk
allele frequency
PubMed ID
Cancer linked NCDs cluster
5p15.33, TERT rs2736100 Glioma 2.00E-17 0.49 19578367
rs2736100 Glioma 1.00E-14 NR 21531791
rs2736100 Glioma 7.00E-09 NR 21827660
rs2736100 Hematological and biochemical traits 3.00E-08 0.4 20139978
rs2736100 Idiopathic pulmonary fibrosis 3.00E-08 0.41 18835860
rs2736100 Lung adenocarcinoma 2.00E-22 0.39 20700438
rs2736100 Lung adenocarcinoma 3.00E-11 0.39 20871597
rs2736100 Lung cancer 1.00E-27 0.41 21725308
rs2736100 Testicular germ cell cancer 8.00E-15 0.49 20543847
5p15.33, TERT, CLPTM1L rs401681 Bladder cancer 5.00E-07 0.54 20972438
rs401681 Lung cancer 8.00E-09 NR 18978787
rs401681 Melanoma 3.00E-08 0.46 21983787
rs401681 Pancreatic cancer 7.00E-07 0.45 20101243
rs401681 Serum prostate-specific antigen levels 1.00E-10 0.55 21160077
8q24.21, Intergenic rs6983267 Colorectal cancer 1.00E-14 0.49 17618284
rs6983267 Colorectal cancer 7.00E-11 0.48 18372905
rs6983267 Colorectal cancer 2.00E-08 0.34 21242260
rs6983267 Prostate cancer 9.00E-13 0.5 17401363
rs6983267 Prostate cancer 9.00E-13 0.49 18264097
rs6983267 Prostate cancer 7.00E-12 0.53 18264096
rs6983267 Prostate cancer 9.00E-06 NR 21743057
9p21.3, CDKN2A, CDKN2B rs4977756 Glaucoma 1.00E-14 0.6 21532571
rs4977756 Glioma 7.00E-15 0.6 19578367
Inflammatory trait linked NCDs cluster
1p31.3, IL23R rs11209026 Ankylosing spondylitis 2.00E-17 0.93 21743469
rs11209026 Ankylosing spondylitis 9.00E-14 0.94 20062062
rs11209026 Crohn’s disease 1.00E-64 0.93 21102463
rs11209026 Crohn’s disease 4.00E-21 NR 22293688
rs11209026 Crohn’s disease 2.00E-18 0.92 17447842
rs11209026 Inflammatory bowel disease 4.00E-11 0.93 17068223
rs11209026 Inflammatory bowel disease 7.00E-11 0.94 18758464
rs11209026 Psoriasis 7.00E-07 NR 20953190
rs11209026 Ulcerative colitis 5.00E-28 0.94 21297633
rs11209026 Ulcerative colitis 3.00E-10 NR 19915572
rs11209026 Ulcerative colitis 1.00E-08 0.93 19122664
1p13.2, PTPN22 rs2476601 Crohn’s disease 1.00E-08 0.9 18587394
rs2476601 Rheumatoid arthritis 9.00E-74 0.1 20453842
rs2476601 Rheumatoid arthritis 2.00E-21 NR 19503088
rs2476601 Rheumatoid arthritis 2.00E-11 0.1 17804836
rs2476601 Type 1 diabetes 9.00E-85 NR 19430480
rs2476601 Type 1 diabetes 2.00E-80 0.09 17554260
rs2476601 Type 1 diabetes 1.00E-07 0.09 17632545
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Table 3 Pleiotropic GWAS loci of NCDs (Continued)
rs2476601 Type 1 diabetes autoantibodies 2.00E-111 NR 21829393
rs2476601 Vitiligo 1.00E-07 0.1 20410501
7q32.1, IRF5,TNPO3 rs10488631 Primary biliary cirrhosis 3.00E-10 0.11 20639880
rs10488631 Primary biliary cirrhosis 2.00E-07 NR 19458352
rs10488631 Rheumatoid arthritis 4.00E-11 0.11 20453842
rs10488631 Systemic lupus erythematosus 7.00E-18 0.11 21408207
rs10488631 Systemic lupus erythematosus 2.00E-11 0.12 18204098
rs10488631 Systemic sclerosis 2.00E-13 NR 20383147
rs10488631 Systemic sclerosis 2.00E-10 NR 21779181
rs10488631 Systemic sclerosis 2.00E-07 NR 21779181
rs10488631 Systemic sclerosis 4.00E-07 0.09 21750679
18p11.21, PTPN2 rs2542151 Crohn’s disease 5.00E-17 0.15 18587394
rs2542151 Crohn’s disease 3.00E-08 0.18 17554261
rs2542151 Crohn’s disease 2.00E-07 0.16 17554300
rs2542151 Type 1 diabetes 1.00E-14 0.16 17554260
rs2542151 Type 1 diabetes 9.00E-08 NR 18978792
rs2542151 Type 1 diabetes autoantibodies 4.00E-13 NR 21829393
18p11.21, PTPN2 rs1893217 Celiac disease 3.00E-10 0.17 20190752
rs1893217 Celiac disease and Rheumatoid arthritis 5.00E-12 NR 21383967
rs1893217 Type 1 diabetes 4.00E-15 NR 19430480
Cardiovascular trait linked NCDs cluster
2p23.3, GCKR rs1260326 Cardiovascular disease risk factors 2.00E-08 0.4 21943158
rs1260326 Cholesterol, total 7.00E-27 0.41 20686565
rs1260326 Chronic kidney disease 3.00E-14 0.41 20383146
rs1260326 C-reactive protein 5.00E-40 NR 21300955
rs1260326 Hematological and biochemical traits 4.00E-09 0.44 20139978
rs1260326 Hypertriglyceridemia 7.00E-09 0.41 20657596
rs1260326 Liver enzyme levels (gamma-glutamyl transferase) 4.00E-13 0.38 22001757
rs1260326 Metabolic traits 4.00E-10 0.35 19060910
rs1260326 Platelet counts 9.00E-10 NR 22139419
rs1260326 Serum metabolites 3.00E-18 NR 22286219
rs1260326 Triglycerides 6.00E-133 0.41 20686565
rs1260326 Triglycerides 2.00E-31 0.45 19060906
rs1260326 Two-hour glucose challenge 3.00E-10 NR 20081857
rs1260326 Waist circumference and related phenotypes 4.00E-08 NR 18454146
11q12.2, FADS1, FADS2 rs174547 HDL cholesterol 2.00E-12 0.33 19060906
rs174547 Lipid metabolism phenotypes 8.00E-262 NR 22286219
rs174547 Metabolic traits 9.00E-116 0.32 21886157
rs174547 Phospholipid levels (plasma) 4.00E-154 NR 21829377
rs174547 Phospholipid levels (plasma) 3.00E-64 NR 21829377
rs174547 Resting heart rate 2.00E-09 0.33 20639392
rs174547 Serum metabolites 7.00E-179 0.3 20037589
rs174547 Triglycerides 2.00E-14 0.33 19060906
11q14.3, MTNR1B rs1387153 Fasting plasma glucose 2.00E-36 0.29 19060909
rs1387153 Glycated hemoglobin levels 4.00E-11 0.28 20858683
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Table 3 Pleiotropic GWAS loci of NCDs (Continued)
rs1387153 Metabolic syndrome (bivariate traits) 2.00E-09 NR 21386085
rs1387153 Metabolic syndrome (bivariate traits) 8.00E-09 NR 21386085
rs1387153 Type 2 diabetes 8.00E-15 NR 20581827
12q24.12, ALDH2, BRAP rs671 Coronary heart disease 2.00E-34 0.23 21971053
rs671 Drinking behavior 4.00E-211 0.75 21372407
rs671 Esophageal cancer 3.00E-24 NR 19698717
rs671 Hematological and biochemical traits 7.00E-10 0.26 20139978
rs671 Hematological and biochemical traits 5.00E-09 0.26 20139978
rs671 Intracranial aneurysm 3.00E-06 0.75 22286173
rs671 Triglycerides 2.00E-06 NR 22171074
16q13, CETP rs3764261 Age-related macular degeneration 7.00E-09 0.33 21665990
rs3764261 Age-related macular degeneration 7.00E-07 0.32 20385819
rs3764261 Cholesterol, total 7.00E-14 0.32 20686565
rs3764261 HDL cholesterol 2.00E-57 0.31 18193043
rs3764261 HDL cholesterol 7.00E-29 0.28 19060910
rs3764261 HDL cholesterol 3.00E-12 0.2 19359809
rs3764261 HDL cholesterol 7E-380 0.32 20686565
rs3764261 LDL cholesterol 9.00E-13 0.32 20686565
rs3764261 Lipid metabolism phenotypes 1.00E-36 NR 22286219
rs3764261 Metabolic syndrome 1.00E-48 0.36 20694148
rs3764261 Metabolic syndrome 3.00E-13 NR 21386085
rs3764261 Triglycerides 1.00E-12 0.45 20686565
rs3764261 Waist circumference 1.00E-27 NR 18454146
19p13.2, LDLR rs6511720 Cardiovascular disease risk factors 5.00E-11 0.11 21943158
rs6511720 Carotid intima media thickness 1.00E-07 NR 21909108
rs6511720 Cholesterol, total 7.00E-97 0.11 20686565
rs6511720 LDL cholesterol 4.00E-117 0.11 20686565
rs6511720 LDL cholesterol 2.00E-51 0.1 18193044
rs6511720 LDL cholesterol 2.00E-26 0.1 19060906
rs6511720 LDL cholesterol 4.00E-26 0.9 18193043
rs6511720 Lp-PLA2 activity and mass 3.00E-11 0.1 22003152
19q13.32, APOE, APOC1 rs4420638 Alzheimer’s disease 2.00E-44 NR 17998437
rs4420638 Alzheimer’s disease 1.00E-39 NR 17975299
rs4420638 Alzheimer’s disease (age of onset) 1.00E-12 NR 22005931
rs4420638 Alzheimer’s disease (late onset) 1.00E-39 NR 17474819
rs4420638 Cholesterol, total 5.00E-111 0.17 20686565
rs4420638 Cognitive decline 4.00E-27 NR 22054870
rs4420638 C-reactive protein 9.00E-139 NR 21300955
rs4420638 C-reactive protein 5.00E-27 NR 19567438
rs4420638 C-reactive protein 3.00E-07 0.9 21196492
rs4420638 HDL cholesterol 4.00E-21 0.17 20686565
rs4420638 LDL cholesterol 9.00E-147 0.17 20686565
rs4420638 LDL cholesterol 1.00E-60 0.2 18193044
rs4420638 LDL cholesterol 3.00E-43 0.18 18193043
rs4420638 LDL cholesterol 2.00E-40 0.18 20864672
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Table 3 Pleiotropic GWAS loci of NCDs (Continued)
rs4420638 LDL cholesterol 4.00E-27 0.16 19060906
rs4420638 LDL cholesterol 1.00E-20 0.18 18262040
rs4420638 LDL cholesterol 2.00E-07 NR 18802019
rs4420638 Lp-PLA2 activity and mass 5.00E-30 0.84 22003152
rs4420638 Lp-PLA2 activity and mass 6.00E-24 0.16 20442857
rs4420638 Longevity 2.00E-16 0.81 21740922
rs4420638 Quantitative traits 3.00E-07 0.21 19197348
rs4420638 Triglycerides 3.00E-13 0.22 17463246
Cardiovascular & inflammatory trait linked NCDs cluster
12q24.12, SH2B3 rs3184504 Coronary heart disease 6.00E-06 0.44 21378990
rs3184504 Diastolic blood pressure 4.00E-25 0.47 21909115
rs3184504 Diastolic blood pressure 3.00E-14 0.48 19430479
rs3184504 Eosinophil counts 7.00E-19 0.38 19198610
rs3184504 Rheumatoid arthritis 6.00E-06 0.51 20453842
rs3184504 Systolic blood pressure 5.00E-09 0.48 19430479
rs3184504 Type 1 diabetes 3.00E-27 NR 19430480
rs3184504 Type 1 diabetes autoantibodies 2.00E-38 NR 21829393
12q24.12, SH2B3, ATXN2 rs653178 Blood pressure 7.00E-20 0.59 21909110
rs653178 Celiac disease 7.00E-21 0.5 20190752
rs653178 Celiac disease 8.00E-08 0.48 18311140
rs653178 Celiac disease and Rheumatoid arthritis 3.00E-19 NR 21383967
rs653178 Chronic kidney disease 4.00E-11 0.5 20383146
rs653178 Diastolic blood pressure 3.00E-18 0.53 19430483
Skin pigmentation linked NCDs cluster
11q14.3, TYR rs1393350 Blue vs. green eyes 3.00E-12 0.23 17952075
rs1393350 Eye color 3.00E-09 0.27 20585627
rs1393350 Melanoma 2.00E-14 0.27 19578364
rs1393350 Melanoma 2.00E-13 0.28 21983787
rs1393350 Skin sensitivity to sun 2.00E-06 0.27 17952075
rs1393350 Tanning 2.00E-13 NR 19340012
rs1393350 Vitiligo 2.00E-18 0.73 20410501
16q24.3, MC1R rs1805007 Basal cell carcinoma 4.00E-17 0.07 21700618
rs1805007 Blond vs. brown hair color 2.00E-13 0.08 17952075
rs1805007 Freckles 1.00E-96 0.05 17952075
rs1805007 Red vs non-red hair color 2.00E-142 NR 17952075
rs1805007 Skin sensitivity to sun 2.00E-55 0.06 17952075
A selection of GWAS identified pleiotropic SNPs implicated in more than one NCD entity are presented here. For a more complete list of pleiotropic loci see
Additional file 1. Data has been downloaded (09 March 2012) from the online catalogue of published GWAS available at www.genome.gov/gwastudies.
NR, not reported.
Lp-PLA2, lipoprotein-associated Phospholipase A2.
LDLR, Low density lipoprotein receptor.
HDL, High density lipoprotein.
LDLR, Low density lipoprotein.
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http://www.biomedcentral.com/1471-2458/13/1094to disease and aging [79], to biologic signals in general
[80] and chaotic motifs have been investigated in dynamic
behavior of gene regulatory networks [81]. To date we have
only started to investigate disease clusters and pleiotropicrisk effects in a systematic manner [82,83]. Formal ana-
lytical concepts of disease similarities and shared gene
networks have been proposed to guide future research for
the identification of molecular evidence of comorbidities
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http://www.biomedcentral.com/1471-2458/13/1094[84]. Recent novel data mining approaches to combine
GWAS findings and phenome data have been proposed to
achieve NCD disease gene discovery, phenotype classifica-
tion [41] and phenome-wide association studies [85] or to
improve disease diagnostic procedures [27,86]. Other
bioinfomatic approaches combining animal model data of
human disease and mammalian phenotype ontologies
databases seem to suggest that germline genetic variation
might underlie the heterogeneity of comorbidities [87,88].
Summary
In the present report, we covered a wide range of aspects
of importance to NCD research, including establishments
and maintenance of large and systematic biobank cohorts
from all parts of the world; implementation of broad and
detailed phenotyping, as well as broad and detailed risk
factor assessment, including aging characteristics; devel-
opment of novel analytical methods for systemic analysis,
addressing networks of diseases, or of personal and envir-
onmental risk factors, as well application of agnostic
genomic analysis methods. In fact, to meet current and
future public health challenges and to improve efficacy
of prevention at the individual as well as at the population
level, we need answers to the following questions [89-92]:
Which are major pathophysiologic pathways mediating
the clustering of NCDs? To what degree are biological
mechanisms shared between NCDs and normal aging? Do
modifiable NCD risk factors act through common mecha-
nisms? Can persons susceptible to common NCD risk
patterns and comorbidities be identified?
To address this type of questions with data providing
adequate statistical power and using hypothesis driven and
explorative as well as agnostic approaches, establishment
and maintenance of carefully designed large and compre-
hensive population-based cohorts with prospective collec-
tion of biological samples are a key requirement. Efforts
must be further intensified to collaborate across cohorts
from different geographic regions in a harmonized fashion,
a process already started with remarkable success in P3G
[93]. Harmonized and exhaustive phenotype collection is a
particular challenge and novel instruments as developed
for standardized assessment of multiple chronic diseases
etiology [94] must be implemented. The quality man-
agement of a sustainable long-term biobank importantly
comprises next to legislative, ethical and financial aspects
also guaranteed safety of samples, temperature monitoring,
traceability and parsimonious use of sample aliquots.
Quality management of biological sample collection is
particularly important for cohort studies with multi-centric
design.
Given that biobank cohorts serve to increase the
wellbeing of future generations by indirectly promoting
biomedical knowledge and public health, these activities
require the development of normative procedures anddefined governance [95,96]. There are still issues left to
be resolved, such as establishing large biobanks for
investigation of future research questions conflicts with
the well accepted and widely implemented personal in-
formed consent [97]. In the light of biobanking’s interest
for present and future society, it might be considered a
great good [95] and according discussions for a possibility
of general non-personalized consent in politics and public
are needed. This debate paper aimed to highlight the
potential of biobank cohort research for complex disease
etiology, a field of research that will allow improving
health of populations as well as informing individuals on
quality-of life increasing health decisions.
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